#4D MOLECULAR THERAPEUTICS LOGO REGISTRATION#

These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Ī registration statement relating to these securities has been filed with the SEC but has not yet become effective. LLC, SVB Leerink and Evercore ISI are acting as joint book-running managers for the proposed offering. All of the shares in the proposed offering are to be sold by 4D Molecular Therapeutics.

4D Molecular Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock offered in the proposed offering. 26, 2021 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it has commenced an underwritten public offering of 4,500,000 shares of its common stock. No representation is made as to the safety or effectiveness of 4D-150, 4D-710, 4D-310, 4D-125, or 4D-110 for the therapeutic uses for which they are being studied.ĤD Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.EMERYVILLE, Calif., Oct. The 4D preclinical product candidates in development are: 4D-175 for geographic atrophy and 4D-725 for AATLD.ĤD-150, 4D-710, 4D-310, 4D-125, and 4D-110 are our product candidates in clinical development and have not yet been approved for marketing by the US FDA or any other regulatory authority. 4DMT is currently advancing five product candidates in clinical development: 4D-150 for wet AMD and DME, 4D-710 for cystic fibrosis lung disease, 4D-310 for Fabry disease cardiomyopathy, 4D-125 for XLRP, and 4D-110 for choroideremia. The 4DMT customized and evolved vectors were invented with the goal of being delivered at relatively low doses through clinically routine, well-tolerated, and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. The Company is initially focused on five clinical-stage product candidates in three therapeutic areas for both rare and large market diseases: ophthalmology, pulmonology, and cardiology. All of our vectors are proprietary to 4DMT and were invented at 4DMT, including the vectors utilized in our clinical-stage and preclinical pipeline product candidates: R100, A101, and C102.

#4D MOLECULAR THERAPEUTICS LOGO FULL#

4DMT seeks to unlock the full potential of genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution, which combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our product candidates. ĤDMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases. Goldman Sachs Global Healthcare Conference Fireside Chat Date:Īrchived copies of the webcasts will be available for up to one year by visiting the “Investors” section of the 4DMT website at. Jefferies Global Healthcare Conference Fireside Chat Date: (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today it will participate in the following upcoming investor conferences: EMERYVILLE, Calif., J(GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc.

4d molecular therapeutics logo